ANA598 Demonstrates 73% cEVR in Combination With Interferon and Ribavirin

Thursday, February 25, 2010 Medical PDA News
Email Print This Page Comment bookmark
Font : A-A+

No Viral Rebound Observed During 12 Weeks of ANA598 Dosing

Proportion of Patients with Undetectable Levels of Virus (<15 IU/mL) by Week

Week 4

(RVR)

Week 6

Week 8

Week 10

Week 12*

(cEVR)

ANA598 + SOC

56%

65%

69%

73%

73%

Placebo+ SOC

20%

27%

47%

54%

71%



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook